27results about "Neurotensin" patented technology

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula(SEQ ID NO: 1)X1X2X3X4X5GVX6AKAGVX7NX8FKSESY(I)(SEQ ID NO: 2)(X9)nGVX10AKAGVX11NX12FKSESY(II)(SEQ ID NO: 3)YKX13LRRX14APRWDX15PLRDPALRX16X17L(III)(SEQ ID NO: 4)YKX18LRR(X19)nPLRDPALRX20X21L(IV)(SEQ ID NO: 5)IKLSGGVQAKAGVINMDKSESM(V)(SEQ ID NO: 6)IKLSGGVQAKAGVINMFKSESY(VI)(SEQ ID NO: 7)IKLSGGVQAKAGVINMFKSESYK(VII)(SEQ ID NO: 8)GVQAKAGVINMFKSESY(VIII)(SEQ ID NO: 9)GVRAKAGVRNMFKSESY(IX)(SEQ ID NO: 10)GVRAKAGVRN(Nle)FKSESY(X)(SEQ ID NO: 11)YKSLRRKAPRWDAPLRDPALRQLL(XI)(SEQ ID NO: 12)YKSLRRKAPRWDAYLRDPALRQLL(XII)(SEQ ID NO: 13)YKSLRRKAPRWDAYLRDPALRPLL(XIII)wherein X1 to X21 and n can have various different valuesand wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end.

A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

The invention belongs to the technical field of biological medicines, and particularly relates to a composite active polypeptide composition with a weight losing effect and a preparation method thereof. The composite active polypeptide composition comprises NT analogue polypeptide ELP3, mulberry leaf polypeptide, balsam pear polypeptide, sea cucumber polypeptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is as shown in SEQ ID NO. 1. According to the present invention, the artificial peptide fragment AYYKSQWLVNGEGTP is added to the end of the wild type NT, such that the gastric acid secretion can be inhibited, and the activity of the alpha-amylase can be significantly inhibited; the NT analogue polypeptide ELP3 and various polypeptide components are matched to achieve a synergistic effect, so that the blood fat metabolism condition of obese mice can be effectively improved, and the fat weight of the mice is reduced; meanwhile, the food intake of the mice can be remarkably inhibited, so that the purpose of reducing the weight of the mice is achieved, and a good weight-losing effect is achieved.

The present invention relates to a nucleic acid molecule encoding a chimeric polypeptide comprising a peptide of interest fused to one or more heterologous moieties, wherein at least one of the heterologous moieties is a ligand of the Sortilin receptor. The invention also relates to a chimeric polypeptide encoded by said nucleic acid molecule and uses thereof.

The present invention relates to a polypeptide comprising a first peptide linked to a second peptide, optionally via a linker molecule, which first peptide comprises an appetite regulating hormone peptide, e.g. glucagon like peptide 1 (GLP-1), such as amino acids 7-37 of the initial GLP-1 product (1-37), and a Neurotensin (NT) like peptide, targeting both the GLP-1 receptor (GLP-1R) and NT receptors (NTR1-3) and display an increased effect on decrease of appetite and food intake and body weight compared to simultaneous administration of both peptides.

The present invention relates to nucleic acid molecules encoding chimeric polypeptides comprising a peptide of interest fused to one or more heterologous moieties, at least one of which is a ligand for a sortilin receptor. The present invention also relates to the chimeric polypeptides encoded by said nucleic acid molecules and uses thereof.

The present invention relates to a novel peptide and its use as a vector for the transport of molecules after conjugation across cellular barriers, in particular the blood-brain barrier (BBB) ​​for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS). Figure 7

The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encoded by the gene SORT 1.

Despite significant progresses made in the treatment of cancers with the development of immune checkpoint inhibitors (ICI), several cancers exhibit resistance to these agents. Certain tumors are considered immunologically cold tumors usually respond poorly to cancer immunotherapies such as immune checkpoint blockade (ICB) therapy, and thus there is a need to develop novel approaches for the treatment of such cancers. The present application discloses methods and uses for enhancing the anti-tumor immune response in a subject suffering from a Sortilin-expressing cancer and / or treating a subject suffering from a Sortilin-expressing cancer, such as a cancer resistant to an immunotherapy, through the administration of conjugate compounds comprising a Sortilin-targeting agent conjugated to an anticancer agent. Combination therapies comprising the conjugate compounds and an immunotherapy such as ICB are also disclosed.

Targeted pharmaceuticals, particularly targeted radiopharmaceuticals, are provided which possess extended tumor retention time.

The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encoded by the gene SORT 1.

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula(I)(SEQ ID NO: 1)X1X2X3X4X5GVX6AKAGVX7NX8FKSESY(II)(SEQ ID NO: 2)(X9)nGVX10AKAGVX11NX12FKSESY(III)(SEQ ID NO: 3)YKX13LRRX14APRWDX15PLRDPALRX16X17L(IV)(SEQ ID NO: 4)YKX18LRR(X19)nPLRDPALRX20X21L(V)(SEQ ID NO: 5)IKLSGGVQAKAGVINMDKSESM(VI)(SEQ ID NO: 6)IKLSGGVQAKAGVINMFKSESY(VII)(SEQ ID NO: 7)IKLSGGVQAKAGVINMFKSESYK(VIII)(SEQ ID NO: 8)GVQAKAGVINMFKSESY(IX)(SEQ ID NO: 9)GVRAKAGVRNMFKSESY(X)(SEQ ID NO: 10)GVRAKAGVRN(Nle)FKSESY(XI)(SEQ ID NO: 11)YKSLRRKAPRWDAPLRDPALRQLL(XII)(SEQ ID NO: 12)YKSLRRKAPRWDAYLRDPALRQLL(XIII)(SEQ ID NO: 13)YKSLRRKAPRWDAYLRDPALRPLLwherein X1 to X21 and n can have various different valuesand wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end.

The present invention relates to bifunctional molecules containing a protein binding moiety of interest linked by a linker group to a cellular receptor binding moiety, preferably a moiety that binds to a receptor sort protein encoded by the gene SORT1.

The present invention relates to a novel peptide and its use as a vector for transporting molecules after conjugation across cell barriers, in particular the blood-brain barrier (BBB) for the diagnosis, prognosis or treatment of central nervous system (CNS) disorders.

The present disclosure relates to peptide compounds and conjugated compounds, processes, methods and uses thereof for treating cancer or invasive cancer. For example, the compound may include a compound of the following formula: X1X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 1), (X9) n GVX 10 AKAGVX 11 NX 12 FKSESY(II)(SEQ ID NO: 2), YKX 13 LRRX 14 APRW 15 PLRDPALRX 16 X 17 L(III) (SEQ ID NO: 3), YKX 18 LRR(X 19 ) N PLRDPALRX 20 X 21 L(IV)(SEQ ID NO:4), IKLSGGVQAKAGVINMDKSESM(V)(SEQ ID NO:5), IKLSGGVQAKAGVINMFKSESY(VI)(SEQ ID NO:6), IKLSGGVQAKAGVINMFKSESYK(VII)(SEQ ID NO:7), GVQAKAGVINMFKSESY(VIII)(SEQ ID NO: 8), GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9), GVRAKAGVRN (Nle) FKSESY (X) (SEQ ID NO: 10), YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11), YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12), YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13), where X1 to X 21 and n can have various values, and wherein at least one protecting group and / or at least one labeling agent is optionally linked to the peptide compound at the N- and / or C-terminus for inhibiting angiogenic mimicry and / or treating cancer.

A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

Despite the development of an immune checkpoint inhibitor (ICI), cancer treatment has gained significant progress, but several cancers still exhibit resistance to these agents. Certain tumors are considered to be immune cold tumors, which are typically poorly responsive to cancer immunotherapies such as immune checkpoint blocking (ICB) therapies, and thus there is a need to develop new methods for treating such cancers. Disclosed herein are methods for enhancing an anti-tumor immune response and / or treating a subject suffering from a sortin-expressing cancer by administering a conjugate compound comprising a sortin targeting agent conjugated to an anti-cancer agent, methods and uses in subjects suffering from cancer, such as cancer that is resistant to immunotherapy. Combination therapies comprising the conjugate compounds and an immunotherapy such as ICB are also disclosed.

Despite important advances in cancer treatment due to the development of immune checkpoint inhibitors (ICIs), some cancers exhibit resistance to these agents. Because certain tumors are considered immunologically cold tumors and typically respond poorly to cancer immunotherapies, such as immune checkpoint blockade (ICB) therapy, there is a need to develop new approaches for the treatment of such cancers. The present application discloses methods and uses for enhancing anti-tumor immune responses in subjects suffering from sortilin-expressing cancers and / or treating subjects suffering from sortilin-expressing cancers, such as cancers resistant to immunotherapy, through the administration of conjugate compounds comprising a sortilin-targeting agent linked to an anticancer drug. Combination therapies comprising the conjugate compounds and immunotherapies, such as ICB, are also disclosed.

To provide a therapeutic polypeptide having improved stability in the plasma compartment, or enhanced uptake by the targeted tissues where it is intended to exert its therapeutic activity.SOLUTION: The present invention relates to a nucleic acid molecule encoding a chimeric polypeptide comprising a peptide of interest fused to one or more heterologous moieties, wherein at least one of the heterologous moieties is a ligand of the Sortilin receptor.SELECTED DRAWING: None

The present invention provides antibodies or antigen-binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to and translocate the blood-brain barrier and methods of use.

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer relating to compound of formula YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) and wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end.

The present invention provides antibodies or antigen-binding fragments thereof including single chain variable fragment (scFv) antibodies that specifically bind to and translocate the blood-brain barrier and methods of use.

The present application belongs to the technical field of biological medicine, and particularly relates to a compound active polypeptide composition with weight loss effect and a preparation method thereof. The compound active polypeptide composition comprises: NT analogue polypeptide ELP3, mulberry leaf polypeptide, bitter gourd polypeptide, sea cucumber peptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is shown as SEQ ID NO. 1. The present application adds an artificial peptide segment AYYKSQWLVNGEGTP to the end of the wild type NT, has the activities of inhibiting gastric acid secretion and obviously inhibiting alpha-amylase. The NT analogue polypeptide ELP3 and the various polypeptide components play a synergistic effect, can effectively improve the blood lipid metabolism of obese mice, reduce the fat weight of the mice, can significantly inhibit the food intake of the mice, so as to achieve the purpose of reducing the body weight of the mice, and shows a good weight loss effect.

The present invention relates to a novel peptide and its use as a vector for transporting molecules after conjugation across cell barriers, in particular the blood-brain barrier (BBB) for the diagnosis, prognosis or treatment of central nervous system (CNS) disorders.

Analogs for CLR / RAMP receptor ligands are provided that have agonist, superagonist, antagonist, super-antagonist, or multiple receptor modulatng activity. The analogs can be selective for one or more CLR / RAMP receptors, or can be pan-specific for multiple G protein-coupled receptors.